The Future of Combination Treatment With Checkpoint Inhibitors in Melanoma

摘要

RS So far, the only approved option is the combination of the anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) agent ipilimumab (Yervoy, Bristol-Myers Squibb) and the anti—programmed death 1 (PD-1) agent nivolumab (Opdivo, Bristol-Myers Squibb). The regimen consists of intravenous (IV) nivolumab at 1 mg/kg and ipilimumab at 3 mg/kg every 3 weeks for up to 4 doses, followed by single-agent nivolumab at 3 mg/kg every 2 weeks until progression or unacceptable toxic effects.